Evidence map›Paper›PMID 25834519›Full record

ArticleAfrican health sciences2014

Splanchnic venous thrombosis driven by a constitutively activated JAK2 V617F philadelphia-negative myeloproliferative neoplasm: a case report.

Musa Waiswa, Emmanuel Seremba, Ponsiana Ocama, Henry Ddungu, Keneth Opio, Clement Okello, Timothy O'shea, Madeleine Verhovsek, Richard Mutyabule

Open access · diamondAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in African health sciences, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 46% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Editorial.African health sciences · 2014
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 3 countries.

Musa WaiswaDepartment of Medicine, Makerere University College of Health Sciences, Mulago Hospital, Kampala, Uganda.
Emmanuel SerembaDepartment of Medicine, Makerere University College of Health Sciences, Mulago Hospital, Kampala, Uganda.
Ponsiana OcamaDepartment of Medicine, Makerere University College of Health Sciences, Mulago Hospital, Kampala, Uganda.
Henry DdunguDepartment of Medicine, Makerere University College of Health Sciences, Mulago Hospital, Kampala, Uganda.
Keneth OpioDepartment of Medicine, Makerere University College of Health Sciences, Mulago Hospital, Kampala, Uganda.
Clement OkelloDepartment of Medicine, Makerere University College of Health Sciences, Mulago Hospital, Kampala, Uganda.
Timothy O'sheaDepartment of Medicine, McMaster University, Hamilton Ontario, Canada.
Madeleine VerhovsekDepartment of Medicine, McMaster University, Hamilton Ontario, Canada.
Richard MutyabuleBrigham and Women's Hospital Boston.
Makerere University · UGMulago Hospital · UGMcMaster University · CABrigham and Women's Hospital · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionSplanchnic venous thrombosis (SVT) has varied etiology with Philadelphia-negative myeloproliferative neoplasms (MPNs) being the most frequent underlying prothrombotic factor. Hematological indices often remain within normal range because of portal hypertension and its sequelae, causing diagnostic challenges. The high frequency of JAK2 mutation among patients with SVT reinforces the diagnostic utility of JAK2V617F testing. CASE REPORT: We report a case of a 62-year-old black man with progressive abdominal swelling and features of decompensated chronic liver disease found to have SVT-portal vein thrombosis and how JAK2 V617F was useful in unmasking an underlying myeloproliferative neoplasm.

conclusionA high index of suspicion for an underlying prothrombotic factor is critical for patients presenting with thrombosis in unusual sites. This is useful in prognostic stratification and patient outcomes. JAK2 mutation screening is now part of the standard diagnostic workup in SVT.

Indexed as

Fatal OutcomeHematologic NeoplasmsHumansJanus Kinase 2MaleMiddle AgedMutationMyeloproliferative DisordersPhiladelphia ChromosomePortal VeinSplanchnic CirculationUltrasonography, DopplerVenous ThrombosisJAK2 protein, humanJanus Kinase 2myeloproliferative neoplasmvenous thrombosis

Identifiers

PMID25834519
PMCPMC4370089
OpenAlexW2102934344

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.